How much does a box of lenvatinib/lenvatinib currently cost?

Lenvatinib/Lenvatinib (Lenvatinib) is a multi-target tyrosine kinase inhibitor (TKI) developed by Japan's Eisai Company. It has the ability to simultaneously inhibit multiple signaling pathways such as VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. This drug inhibits the growth and spread of cancer cells by inhibiting angiogenesis and tumor cell proliferation. It is currently one of the most widely used targeted drugs. Lenvatinib was first approved for marketing in Japan in 2015, and was subsequently approved for use in the United States, Europe and China. It is mainly used to treat various solid tumors such as renal cell carcinoma, hepatocellular carcinoma, thyroid cancer and endometrial cancer. In recent years, with the advancement of real-world research, its potential in combination immunotherapy has gradually emerged, and it is considered one of the important drugs in anti-tumor treatment.

Currently, lenvatinib has been officially launched in China and has been included in the National Reimbursement Directory, which means that patients can obtain drug treatment at a lower out-of-pocket rate. The common domestic specifications are 4mg × 30 tablets. The actual price after medical insurance reimbursement is about 3,000 yuan. The specific price will vary slightly according to regional medical insurance policies and hospital procurement channels. In overseas markets, the original drug of lenvatinib (Japanese or European version) is priced at about 2,000 yuan, while the price of generic drugs from countries such as Laos and Bangladesh is more affordable, ranging from about 400 to 900 yuan per box. Generic drugs are basically the same as original drugs in terms of drug ingredients and dosage. However, due to differences in production processes, approval standards and import channels, patients should follow doctor's advice and purchase through formal channels when choosing.

The efficacy of lenvatinib has been verified in multiple tumor areas. Especially in the treatment of advanced liver cancer, combined with the immune drug pembrolizumab (Keytruda), it has shown the potential to improve overall survival rate. This combination has also become a hot topic in current research.

Reference materials:https://www.lenvima.com/